On the public citation graph

Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease

0 signed · 191 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 45 references listed on this page is in the Retraction Watch database as retracted (export 2026-11-18): 10.1210/jc.2014-2739 (notice 2015-05-01).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/hep.20466openalex-snapshot
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
inferredcites →https://doi.org/10.1002/hep.26156openalex-snapshot
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
inferredcites →https://doi.org/10.1002/hep.27981openalex-snapshot
Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
inferredcites →https://doi.org/10.1002/hep.29367openalex-snapshot
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
inferredcites →https://doi.org/10.1002/hep.29724openalex-snapshot
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1002/hep.30842openalex-snapshot
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
inferredcites →https://doi.org/10.1002/hep4.1054openalex-snapshot
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/oby.23263openalex-snapshot
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1007/s00125-016-3902-yopenalex-snapshot
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1007/s11606-021-06677-wopenalex-snapshot
Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017–2018
inferredcites →https://doi.org/10.1007/s12020-019-02155-wopenalex-snapshot
Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity
inferredcites →https://doi.org/10.1016/j.amjmed.2020.01.007openalex-snapshot
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
inferredcites →https://doi.org/10.1016/j.cgh.2008.08.012openalex-snapshot
Effect of Bariatric Surgery on Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1016/j.cgh.2018.12.031openalex-snapshot
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage
inferredcites →https://doi.org/10.1016/j.cgh.2021.02.009openalex-snapshot
Transient Elastography–Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States
inferredcites →https://doi.org/10.1016/j.diabres.2020.108358openalex-snapshot
Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005–2016
inferredcites →https://doi.org/10.1016/j.jhep.2017.11.013openalex-snapshot
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers
inferredcites →https://doi.org/10.1016/j.jhep.2019.06.021openalex-snapshot
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.jhepr.2019.07.002openalex-snapshot
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
inferredcites →https://doi.org/10.1016/j.soard.2019.01.035openalex-snapshot
Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery
inferredcites →https://doi.org/10.1016/s2213-8587(18)30154-2openalex-snapshot
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
inferredcites →https://doi.org/10.1055/s-0034-1371083openalex-snapshot
Hepatic Pathology among Patients without Known Liver Disease Undergoing Bariatric Surgery: Observations and a Perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study
inferredcites →https://doi.org/10.1097/mcg.0000000000001339openalex-snapshot
Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1111/apt.13012openalex-snapshot
Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey
inferredcites →https://doi.org/10.1111/apt.13405openalex-snapshot
Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
inferredcites →https://doi.org/10.1111/dom.12973openalex-snapshot
Non‐alcoholic fatty liver disease ( NAFLD ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes
inferredcites →https://doi.org/10.1111/jgh.14577openalex-snapshot
Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography
inferredcites →https://doi.org/10.1111/liv.12840openalex-snapshot
Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
inferredcites →https://doi.org/10.1111/liv.14669openalex-snapshot
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
inferredcites →https://doi.org/10.1136/gutjnl-2015-309265openalex-snapshot
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
inferredcites →https://doi.org/10.1136/gutjnl-2020-320622openalex-snapshot
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
inferredcites →https://doi.org/10.1186/1471-230x-6-33openalex-snapshot
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
inferredcites →https://doi.org/10.1210/jc.2014-2739openalex-snapshot
WITHDRAWN: High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels (article published in final form as 10.1210/jc.2015-1966)
inferredcites →https://doi.org/10.1210/jc.2015-1966openalex-snapshot
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
inferredcites →https://doi.org/10.1210/jc.2015-3111openalex-snapshot
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
inferredcites →https://doi.org/10.2337/dc11-1849openalex-snapshot
Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
inferredcites →https://doi.org/10.2337/dc16-1787openalex-snapshot
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
inferredcites →https://doi.org/10.2337/dc19-1071openalex-snapshot
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc19-1113openalex-snapshot
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
inferredcites →https://doi.org/10.2337/dc20-1778openalex-snapshot
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc20-1997openalex-snapshot
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
inferredcites →https://doi.org/10.2337/dc21-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2021
inferredcites →https://doi.org/10.2337/dci19-0064openalex-snapshot
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.3390/jcm10091877openalex-snapshot
Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis
inferredcites →https://doi.org/10.5604/16652681.1212434openalex-snapshot
High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extracted
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.2139/ssrn.4893547openalex-extracted
Prevalence and Risk Factors Associated with Hepatitis C Virus Infection in Patients with Type 2-Diabetes Mellitus; Case Control Study in Lahore, Pakistan
inferred← citeshttps://doi.org/10.1002/1878-0261.13685openalex-snapshot
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives
inferred← citeshttps://doi.org/10.1002/oby.23422openalex-snapshot
Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”
inferred← citeshttps://doi.org/10.1002/oby.23423openalex-snapshot
Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?
inferred← citeshttps://doi.org/10.1002/oby.23960openalex-snapshot
Noninvasive tests to identify liver fibrosis in metabolic dysfunction‐associated steatotic liver disease are affected by race
inferred← citeshttps://doi.org/10.1002/oby.24130openalex-snapshot
Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen
inferred← citeshttps://doi.org/10.1002/oby.70277openalex-snapshot
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-82888-1_10openalex-snapshot
Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1007/978-981-96-3894-9_10openalex-snapshot
Prevention of HCC
inferred← citeshttps://doi.org/10.1007/s11892-024-01558-yopenalex-snapshot
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.1007/s11894-025-00988-2openalex-snapshot
Evolving Role of GLP-1 Therapies in Liver Disease
inferred← citeshttps://doi.org/10.1007/s11901-024-00639-6openalex-snapshot
Endocrinology for the Hepatologist
inferred← citeshttps://doi.org/10.1007/s12072-024-10661-xopenalex-snapshot
MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD
inferred← citeshttps://doi.org/10.1007/s12325-024-03085-4openalex-snapshot
Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database
inferred← citeshttps://doi.org/10.1016/j.ahjo.2024.100457openalex-snapshot
Liver fibrosis according to diabetes status and relation to cardiovascular risk and mortality in US adults
inferred← citeshttps://doi.org/10.1016/j.aohep.2022.100762openalex-snapshot
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
inferred← citeshttps://doi.org/10.1016/j.aohep.2022.100892openalex-snapshot
Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.aohep.2023.101177openalex-snapshot
Non-linear associations of circulating total bilirubin concentration with the risk of nonalcoholic fatty liver disease and all-cause mortality
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.115502openalex-snapshot
Pathophysiology of diabetic hepatopathy and molecular mechanisms underlying the hepatoprotective effects of phytochemicals
inferred← citeshttps://doi.org/10.1016/j.cgh.2023.12.009openalex-snapshot
Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD
inferred← citeshttps://doi.org/10.1016/j.cgh.2024.01.032openalex-snapshot
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.cgh.2024.03.006openalex-snapshot
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.cgh.2024.04.017openalex-snapshot
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
inferred← citeshttps://doi.org/10.1016/j.diabres.2023.110993openalex-snapshot
Association between nonalcoholic fatty liver disease and type 2 diabetes: A bidirectional two-sample mendelian randomization study
inferred← citeshttps://doi.org/10.1016/j.diabres.2024.111648openalex-snapshot
Epidemiology of NAFLD – Focus on diabetes
inferred← citeshttps://doi.org/10.1016/j.dld.2025.05.023openalex-snapshot
Multiparametric magnetic resonance imaging may improve detection of patients with at-risk MASH: Real world experience in hepatology clinics
inferred← citeshttps://doi.org/10.1016/j.dsx.2025.103209openalex-snapshot
Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.ecoenv.2022.114361openalex-snapshot
Integration of metabolomics and proteomics reveals the underlying hepatotoxic mechanism of perfluorooctane sulfonate (PFOS) and 6:2 chlorinated polyfluoroalkyl ether sulfonic acid (6:2 Cl-PFESA) in primary human hepatocytes
inferred← citeshttps://doi.org/10.1016/j.ecoenv.2025.117762openalex-snapshot
Associations between brominated flame retardants exposure and non-alcoholic fatty liver disease: Mediation analysis in the NHANES
inferred← citeshttps://doi.org/10.1016/j.endmts.2025.100218openalex-snapshot
Effects of a novel weight-loss combination product containing orlistat and resveratrol on obesity: A multicenter randomized controlled study (EC-FIT)
inferred← citeshttps://doi.org/10.1016/j.envpol.2022.119915openalex-snapshot
Analysis of environmental chemical mixtures and nonalcoholic fatty liver disease: NHANES 1999–2014
inferred← citeshttps://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferred← citeshttps://doi.org/10.1016/j.eprac.2023.06.012openalex-snapshot
Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics
inferred← citeshttps://doi.org/10.1016/j.gastha.2026.100923openalex-snapshot
Cost-Effectiveness of Blood-Based Fibrosis Screening in High-Risk Metabolic Liver Diseases With Emerging Therapies
inferred← citeshttps://doi.org/10.1016/j.jceh.2025.103411openalex-snapshot
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
inferred← citeshttps://doi.org/10.1016/j.jep.2022.115268openalex-snapshot
Integrating metabolomics and network pharmacology to reveal the mechanisms of Delphinium brunonianum extract against nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.08.012openalex-snapshot
Dysglycemia and liver lipid content determine the relationship of insulin resistance with hepatic OXPHOS capacity in obesity
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.12.045openalex-snapshot
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
inferred← citeshttps://doi.org/10.1016/j.metabol.2023.155642openalex-snapshot
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
inferred← citeshttps://doi.org/10.1016/j.numecd.2024.09.013openalex-snapshot
Sex-specific association of weight-adjusted waist index with mortality in stroke survivors: A national longitudinal cohort study
inferred← citeshttps://doi.org/10.1016/j.tox.2024.153929openalex-snapshot
Evaluating combined effects of chronic, low-dose exposures of cadmium (CLEC) and hyperglycemia on insulin signaling dysfunction in a hepatocellular model
inferred← citeshttps://doi.org/10.1016/s2213-8587(22)00003-1openalex-snapshot
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
inferred← citeshttps://doi.org/10.1038/s41568-024-00743-1openalex-snapshot
Macrophages and T cells in metabolic disorder-associated cancers
inferred← citeshttps://doi.org/10.1038/s41598-023-46288-5openalex-snapshot
Empagliflozin suppresses hedgehog pathway, alleviates ER stress, and ameliorates hepatic fibrosis in rats
inferred← citeshttps://doi.org/10.1053/j.gastro.2021.07.049openalex-snapshot
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1080/17474124.2023.2197210openalex-snapshot
Impact of donor diabetes mellitus status on liver transplant outcomes in patients with acute-on-chronic liver failure
inferred← citeshttps://doi.org/10.1080/17474124.2024.2388790openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist
inferred← citeshttps://doi.org/10.1093/ajhp/zxaf251openalex-snapshot
Pharmacist-led screening for advanced fibrosis using the FIB-4 index in patients 65 years or older with a clinical suspicion for MASLD at a family medicine clinic
inferred← citeshttps://doi.org/10.1093/fampra/cmag008openalex-snapshot
Can the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?
inferred← citeshttps://doi.org/10.1093/ofid/ofaf369openalex-snapshot
Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction–Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1093/rheumatology/keaf282openalex-snapshot
The lack of association between cumulative MTX dose and liver fibrosis in PsA: a cohort study
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000300openalex-snapshot
Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000571openalex-snapshot
Clinical care guidance in patients with diabetes and metabolic dysfunction–associated steatotic liver disease: A joint consensus
inferred← citeshttps://doi.org/10.1097/hep.0000000000000263openalex-snapshot
Diabetes and cirrhosis: Current concepts on diagnosis and management
inferred← citeshttps://doi.org/10.1097/hep.0000000000000323openalex-snapshot
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1097/hep.0000000000000941openalex-snapshot
Physical exercise in liver diseases
inferred← citeshttps://doi.org/10.1097/mcg.0000000000001780openalex-snapshot
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.1097/mcg.0000000000002321openalex-snapshot
Cannabis Use in Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1097/md.0000000000044109openalex-snapshot
Association between metabolic dysfunction-associated steatotic liver disease and insulin resistance in individuals with normoglycemia
inferred← citeshttps://doi.org/10.1097/meg.0000000000002767openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease
inferred← citeshttps://doi.org/10.1111/apha.14217openalex-snapshot
Beneficial effects of MGL ‐3196 and BAM15 combination in a mouse model of fatty liver disease
inferred← citeshttps://doi.org/10.1111/dom.15153openalex-snapshot
Liver fibrosis markers and all cause mortality in people with type 2 diabetes: A population based study (The Ayrshire Diabetes Outcomes Cohort (ADOC) Study)
inferred← citeshttps://doi.org/10.1111/dom.15524openalex-snapshot
The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis
inferred← citeshttps://doi.org/10.1111/hepr.70089openalex-snapshot
Metabolic Effect on Serum Mac‐2 Binding Protein Glycan Isomer Level and Its Normal Range in the Health Checkup Examinee
inferred← citeshttps://doi.org/10.1111/liv.15864openalex-snapshot
Links between gut microbiome, metabolome, clinical variables and non‐alcoholic fatty liver disease severity in bariatric patients
inferred← citeshttps://doi.org/10.1111/nyas.15259openalex-snapshot
Diabetes and cardiovascular disease in older adults
inferred← citeshttps://doi.org/10.1136/bmjgast-2024-001466openalex-snapshot
Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study
inferred← citeshttps://doi.org/10.1136/bmjmed-2022-000372openalex-snapshot
Advances in the management of type 2 diabetes in adults
inferred← citeshttps://doi.org/10.1136/bmjsem-2023-001878openalex-snapshot
Effect of low-volume exercise on hepatic steatosis in adults with obesity plus normal glucose, prediabetes or type 2 diabetes: a randomised controlled trial
inferred← citeshttps://doi.org/10.1136/flgastro-2024-102856openalex-snapshot
Role of anti-diabetic medications in the management of MASLD
inferred← citeshttps://doi.org/10.1155/jdr/3955893openalex-snapshot
Network Pharmacology and Serum Nontargeted Metabolomics Reveal the Protective Effects of Propionate Against Liver Damage Induced by a High‐Fat and AGE‐Rich Diet in Diabetic Mice
inferred← citeshttps://doi.org/10.1186/s12876-022-02550-0openalex-snapshot
Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study
inferred← citeshttps://doi.org/10.1186/s12889-024-19536-0openalex-snapshot
Smoking, all-cause, and cause-specific mortality in individuals with diabetes in Mexico: an analysis of the Mexico city prospective study
inferred← citeshttps://doi.org/10.1186/s12902-022-01228-8openalex-snapshot
The correlation between triiodothyronine and the severity of liver fibrosis
inferred← citeshttps://doi.org/10.1186/s12902-025-01881-9openalex-snapshot
Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease
inferred← citeshttps://doi.org/10.1186/s12933-022-01691-6openalex-snapshot
The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
inferred← citeshttps://doi.org/10.1210/clinem/dgab578openalex-snapshot
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
inferred← citeshttps://doi.org/10.1210/clinem/dgac186openalex-snapshot
A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now
inferred← citeshttps://doi.org/10.1210/clinem/dgac624openalex-snapshot
Approach to the Patient With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1210/clinem/dgac660openalex-snapshot
Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD
inferred← citeshttps://doi.org/10.1210/endrev/bnag023openalex-snapshot
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
inferred← citeshttps://doi.org/10.12968/indn.2025.7.18openalex-snapshot
Type 2 diabetes and NAFLD part 1: classification and investigations
inferred← citeshttps://doi.org/10.17925/ee.2025.21.1.4openalex-snapshot
The Use of Non-invasive Biomarkers to Screen for Advanced Fibrosis Associated with Metabolic Dysfunction-associated Steatotic Liver Disease in People with Type 2 Diabetes: A Narrative Review
inferred← citeshttps://doi.org/10.18203/2320-6012.ijrms20240665openalex-snapshot
Comparison of non-invasive scores predictive of development of metabolic dysfunction associated liver disease in patients of type 2 diabetes mellitus and evaluation of additive effect of smoking in these patients
inferred← citeshttps://doi.org/10.18553/jmcp.2026.32.10.1289openalex-snapshot
Embedding metabolic dysfunction–associated steatotic liver disease fibrosis risk stratification within pharmacist-integrated diabetes comanagement in primary care
inferred← citeshttps://doi.org/10.20517/mtod.2022.29openalex-snapshot
Screening for advanced liver fibrosis in overweight and obese patients with NAFLD
inferred← citeshttps://doi.org/10.2147/dmso.s375300openalex-snapshot
A Cross-Sectional Study of the Correlation Between the Atherogenic Index of Plasma and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
inferred← citeshttps://doi.org/10.2196/36997openalex-snapshot
Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores
inferred← citeshttps://doi.org/10.2337/dc23-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
inferred← citeshttps://doi.org/10.2337/dc24-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
inferred← citeshttps://doi.org/10.2337/dc25-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
inferred← citeshttps://doi.org/10.2337/dc26-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026
inferred← citeshttps://doi.org/10.2337/dci24-0094openalex-snapshot
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
inferred← citeshttps://doi.org/10.2337/dsi23-0012openalex-snapshot
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
inferred← citeshttps://doi.org/10.2337/dsi23-0013openalex-snapshot
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
inferred← citeshttps://doi.org/10.2337/dsi23-0014openalex-snapshot
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
inferred← citeshttps://doi.org/10.2337/dsi23-0015openalex-snapshot
Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action
inferred← citeshttps://doi.org/10.23736/s0031-0808.22.04730-9openalex-snapshot
Metabolic associated liver disease
inferred← citeshttps://doi.org/10.23736/s0031-0808.23.04850-4openalex-snapshot
Corrected and republished from: Metabolic associated liver disease
inferred← citeshttps://doi.org/10.2478/inmed-2022-0198openalex-snapshot
Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.2478/orvtudert-2024-0011openalex-snapshot
Assessment of laboratory parameters in overweight/obese patients with type 2 diabetes mellitus and their relationship with cardiovascular risk factors
inferred← citeshttps://doi.org/10.26416/med.151.1.2023.7836openalex-snapshot
The complex link between non-alcoholic fatty liver disease and type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.26445/08.03.5openalex-snapshot
Asociación de fibrosis hepática mediante elastografía por shear wave 2D y score APRI
inferred← citeshttps://doi.org/10.26508/lsa.202101209openalex-snapshot
Adipose tissue–specific ablation of Ces1d causes metabolic dysregulation in mice
inferred← citeshttps://doi.org/10.3350/cmh.2024.0705openalex-snapshot
Correspondence on Editorial regarding “Incretin-based therapy in the management of MASLD: one piece of the puzzle”
inferred← citeshttps://doi.org/10.3389/fendo.2022.1051958openalex-snapshot
Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study
inferred← citeshttps://doi.org/10.3389/fendo.2026.1881759openalex-snapshot
Association of the fibrosis-4 index with prevalent diabetes among adults: a cross-sectional analysis of NHANES 2003–2018 and a Chinese hospital-based health examination population
inferred← citeshttps://doi.org/10.3389/fmed.2024.1467773openalex-snapshot
Correlation between hepatic steatosis severity diagnosed by ultrasound and metabolic indexes in elderly patients with MAFLD
inferred← citeshttps://doi.org/10.3389/fnut.2023.1276940openalex-snapshot
Dietary and lifestyle oxidative balance scores are independently and jointly associated with nonalcoholic fatty liver disease: a 20 years nationally representative cross-sectional study
inferred← citeshttps://doi.org/10.3389/fnut.2024.1397429openalex-snapshot
Association of the oxidative balance score with sarcopenia among young and middle-aged adults: findings from NHANES 2011–2018
inferred← citeshttps://doi.org/10.3389/fnut.2024.1476467openalex-snapshot
Association between changes in body composition and progression of liver fibrosis in patients with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.3389/fpubh.2023.1133194openalex-snapshot
Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003–2018
inferred← citeshttps://doi.org/10.3389/ijph.2023.1605031openalex-snapshot
Association Between Physical Activity and Prevalence/Mortality of Non-Alcoholic Fatty Liver Disease in Different Socioeconomic Settings
inferred← citeshttps://doi.org/10.3390/cancers14194868openalex-snapshot
Neuraminidase-1: A Sialidase Involved in the Development of Cancers and Metabolic Diseases
inferred← citeshttps://doi.org/10.3390/diagnostics12071753openalex-snapshot
Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter
inferred← citeshttps://doi.org/10.3390/gastroent14030018openalex-snapshot
Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation
inferred← citeshttps://doi.org/10.3390/ijms251810144openalex-snapshot
Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva
inferred← citeshttps://doi.org/10.3390/jcdd9120419openalex-snapshot
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.3390/jcm11061474openalex-snapshot
Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea
inferred← citeshttps://doi.org/10.3390/jcm12247760openalex-snapshot
Prevalence and Crucial Parameters in Diabesity-Related Liver Fibrosis: A Preliminary Study
inferred← citeshttps://doi.org/10.3390/jcm13082231openalex-snapshot
Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease
inferred← citeshttps://doi.org/10.3390/jpm13040682openalex-snapshot
Overweight/Obesity Increases the Risk of Overt Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients
inferred← citeshttps://doi.org/10.3390/livers6020026openalex-snapshot
Association Among Liver Enzymes, Liver-to-Spleen Hounsfield Unit Ratio, and Glycemic Profiles After Sleeve Gastrectomy in Diabetic and Non-Diabetic Japanese Patients with Obesity: A Retrospective Pilot Study
inferred← citeshttps://doi.org/10.3390/nu14061224openalex-snapshot
The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004
inferred← citeshttps://doi.org/10.3390/nu16010140openalex-snapshot
Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis
inferred← citeshttps://doi.org/10.37349/eemd.2025.101446openalex-snapshot
Diabetes mellitus and hepatosteatosis: a narrative review
inferred← citeshttps://doi.org/10.3748/wjg.v29.i2.286openalex-snapshot
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3803/enm.2022.605openalex-snapshot
DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
inferred← citeshttps://doi.org/10.4093/dmj.2023.0350openalex-snapshot
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
inferred← citeshttps://doi.org/10.4093/dmj.2024.0532openalex-snapshot
Interleukin 33 Promotes Liver Sinusoidal Endothelial Cell Dysfunction and Hepatic Fibrosis in Diabetic Mice
inferred← citeshttps://doi.org/10.4093/jkd.2023.24.3.107openalex-snapshot
Approach to Fatty Liver Disease in Patients with Type 2 Diabetes
inferred← citeshttps://doi.org/10.4103/bjem.bjem_25_24openalex-snapshot
Fibrosis-4 and Ultrasonography Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease: A Cross-sectional, Observational Study
inferred← citeshttps://doi.org/10.4103/ijem.ijem_1075_25openalex-snapshot
Effect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre
inferred← citeshttps://doi.org/10.4103/sjg.sjg_199_25openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards
inferred← citeshttps://doi.org/10.4103/tmj.tmj_48_24openalex-snapshot
Comparisons between different scoring systems in the detection and grading of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.4239/wjd.v14.i11.1621openalex-snapshot
Molecular mechanisms of noncoding RNA and epigenetic regulation in obesity with consequent diabetes mellitus development
inferred← citeshttps://doi.org/10.4254/wjh.120789openalex-snapshot
Protective effects of kaempferol against diet-induced metabolic disorders
inferred← citeshttps://doi.org/10.58495/10.2001/journal.2026/25openalex-snapshot
Metabolic dysfunctionassociated steatotic liver disease in diabetes
inferred← citeshttps://doi.org/10.59556/japi.72.0582openalex-snapshot
Prevalence and Association of Risk Factors According to Liver Steatosis and Fibrosis Stages among Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus in India: A Cross-sectional Study
inferred← citeshttps://doi.org/10.6084/m9.figshare.22601651openalex-snapshot
Additional file 1 of The correlation between triiodothyronine and the severity of liver fibrosis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26550982openalex-snapshot
Additional file 1 of The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
inferred← citeshttps://doi.org/10.71079/aside.gi.022626448openalex-snapshot
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications
inferred← citeshttps://doi.org/10.7189/jogh.13.04138openalex-snapshot
Association between weight change and risk of liver fibrosis in adults with type 2 diabetes
inferred← citeshttps://doi.org/10.7759/cureus.53295openalex-snapshot
Significant Promising Effects of Bariatric Surgery on the Biochemical Control of Glycemia and Lipidemia in Diabetic Patients in Western Saudi Arabia: A Tertiary Center Experience and a Retrospective Study
showing the first 145 of 146 · page through all 146
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.